Tuesday , October 11 2016
Home / Lifestyle / Health / Substitute developed for cancer-resisting Tibetan herb

Substitute developed for cancer-resisting Tibetan herb


Beijing : After eleven years of research, scientists in China have developed a substitute for wild caterpillar fungus, a rare Tibetan herb known for its cancer-resisting properties.

The science department of northwest China’s Qinghai Province said on Friday that scientists can extract and cultivate the hypha from caterpillar fungus by producing an artificial substitute.

The eleven years of research was sponsored by the provincial government, as it wanted to stop depletion of the wild herb, Zhang Chaoyuan, deputy director of the science department told state-run Xinhua news agency.

A tiny stalk of fungus, known in China as “winter worm, summer grass”, sells for about the same price as gold, even in the nearest town to the plateau where it grows.

The wild herb has been an important source of income for ethnic Tibetans living in the region.
However, excessive digging of the fungus, which has a long growing cycle, has led to serious damage to the fragile ecological environment in the region.

Zhang said scientists collected the wild fungus from the Tibetan prefecture of Yushu, which is 4,800 meters above sea level, and used it to produce the artificial substitute, which also possesses the herb’s medical properties.

Found only on the Qinghai-Tibet Plateau, the caterpillar fungus reportedly has cancer fighting properties and boosts the immune system.

During the process of artificial cultivation, scientists removed unnecessary parts and isolated the valuable Cordyceps sinensis (Hirsutella sinensis).

Zhang said the government provided financial and technical support to the project, which will have an annual output of 200 tonnes of the fermented caterpillar fungus powder and by-products.

The artificial product has a 97-per cent DNA similarity with the wild herb, according to Qinghai Everest Cordyceps Pharmaceutical, the research company.

The processed health product earned 135 million yuan ($20 million) in revenue during a trial production.


Read Also


MD Unani mock test at Siasat